# Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

> **NCT03588078** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 53 (actual)

## Conditions studied

- Myelodysplastic Syndrome With Gene Mutation
- Acute Myeloid Leukemia With Gene Mutations
- Myeloproliferative Neoplasm
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** APR-246
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03588078
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-15
- **Primary completion:** 2020-05-01
- **Final completion:** 2021-05-15
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588078, "Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03588078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*